SEC. 2. ENHANCED PUNISHMENT OF AMPHETAMINE LAB-
ORATORY OPERATORS.
(a) AMENDMENT TO FEDERAL SENTENCING GUIDE-
LINES.—Pursuant to its authority under section 994(p)
of title 28, United States Code, the United States Sen-
tencing Commission shall amend the Federal sentencing
guidelines in accordance with this section with respect to
any offense relating to the manufacture, importation, ex-
portation, or trafficking in amphetamine (including an at-
tempt or conspiracy to do any of the foregoing) in violation
of—
(1) the Controlled Substances Act (21 U.S.C.
801 et seq.);
(2) the Controlled Substances Import and Ex-
port Act (21 U.S.C. 951 et seq.); or
(3) the Maritime Drug Law Enforcement Act
(46 U.S.C. App. 1901 et seq.).
(b) GENERAL REQUIREMENT.—In carrying out this
section, the United States Sentencing Commission shall,
with respect to each offense described in subsection (a)
relating to amphetamine—
(1) review and amend its guidelines to provide
for increased penalties such that those penalties are
comparable to the base offense level for meth-
amphetamine; and
(2) take any other action the Commission con-
siders necessary to carry out this subsection.
(c) ADDITIONAL REQUIREMENTS.—In carrying out
this section, the United States Sentencing Commission
shall ensure that the sentencing guidelines for offenders
convicted of offenses described in subsection (a) reflect the
heinous nature of such offenses, the need for aggressive
law enforcement action to fight such offenses, and the ex-
treme dangers associated with unlawful activity involving
amphetamines, including—
(1) the rapidly growing incidence of amphet-
amine abuse and the threat to public safety that
such abuse poses;
(2) the high risk of amphetamine addiction;
(3) the increased risk of violence associated
with amphetamine trafficking and abuse; and
(4) the recent increase in the illegal importation
of amphetamine and precursor chemicals.
(d) EMERGENCY AUTHORITY TO SENTENCING COM-
MISSION.—The United States Sentencing Commission
shall promulgate amendments pursuant to this section as
soon as practicable after the date of the enactment of this
Act in accordance with the procedure set forth in section
21(a) of the Sentencing Act of 1987 (Public Law 100–
182), as though the authority under that Act had not ex-
pired.
SEC. 3. ADVERTISEMENTS FOR DRUG PARAPHERNALIA
AND SCHEDULE I CONTROLLED SUBSTANCES.
(a) DRUG PARAPHERNALIA.—Section 422 of the
Controlled Substances Act (21 U.S.C. 863) is amended—
(1) in subsection (a)(1), by inserting ‘‘, directly
or indirectly advertise for sale,’’ after ‘‘sell’’; and
(2) by adding at the end the following:
‘‘(g) In this section, the term ‘directly or indirectly
advertise for sale’ includes the use of any communication
facility (as that term is defined in section 403(b)) to ini-
tiate the posting, publicizing, transmitting, publishing,
linking to, broadcasting, or other advertising of any mat-
ter (including a telephone number or electronic or mail
address) knowing that such matter has the purpose of
seeking or offering, or is designed to be used, to receive,
buy, distribute, or otherwise facilitate a transaction in.’’.
(b) SCHEDULE I CONTROLLED SUBSTANCES.—Sec-
tion 403(c) of such Act (21 U.S.C. 843(c)) is amended—
(1) in the first sentence, by inserting before the
period the following: ‘‘, or to directly or indirectly
advertise for sale (as that term is defined in section
422(g)) any Schedule I controlled substance’’; and
(2) in the second sentence, by striking ‘‘term
‘advertisement’ ’’ and inserting ‘‘term ‘written adver-
tisement’ ’’.
SEC. 4. MANDATORY RESTITUTION FOR VIOLATIONS OF
CONTROLLED SUBSTANCES ACT AND CON-
TROLLED SUBSTANCES IMPORT AND EXPORT
ACT 
RELATING 
TO 
AMPHETAMINE 
AND
METHAMPHETAMINE.
(a) MANDATORY RESTITUTION.—Section 413(q) of
the Controlled Substances Act (21 U.S.C. 853(q)) is
amended—
(1) in the matter preceding paragraph (1), by
striking ‘‘may’’ and inserting ‘‘shall’’;
(2) by inserting ‘‘amphetamine or’’ before
‘‘methamphetamine’’ each place it appears; and
(3) in paragraph (2)—
(A) by inserting ‘‘, the State or local gov-
ernment concerned, or both the United States
and the State or local government concerned’’
after ‘‘United States’’ the first place it appears;
and
(B) by inserting ‘‘or the State or local gov-
ernment concerned, as the case may be,’’ after
‘‘United States’’ the second place it appears.
(b) DEPOSIT OF AMOUNTS IN DEPARTMENT OF JUS-
TICE ASSETS FORFEITURE FUND.—Section 524(c)(4) of
title 28, United States Code, is amended—
(1) by striking ‘‘and’’ at the end of subpara-
graph (B);
(2) by striking the period at the end of sub-
paragraph (C) and inserting ‘‘; and’’; and
(3) by adding at the end the following:
‘‘(D) all amounts collected—
‘‘(i) by the United States pursuant to a re-
imbursement order under paragraph (2) of sec-
tion 413(q) of the Controlled Substances Act
(21 U.S.C. 853(q)); and
‘‘(ii) pursuant to a restitution order under
paragraph (1) or (3) of section 413(q) of the
Controlled Substances Act for injuries to the
United States.’’.
SEC. 5. CRIMINAL PROHIBITION ON DISTRIBUTION OF CER-
TAIN INFORMATION RELATING TO THE MAN-
UFACTURE OF CONTROLLED SUBSTANCES.
(a) IN GENERAL.—Part I of title 18, United States
Code, is amended by inserting after chapter 21 the fol-
lowing new chapter:
‘‘CHAPTER 22—CONTROLLED
SUBSTANCES
‘‘Sec.
‘‘421. Distribution of information relating to manufacture of controlled sub-
stances.
‘‘§ 421. Distribution of information relating to manu-
facture of controlled substances
‘‘(a) PROHIBITION ON DISTRIBUTION OF INFORMA-
TION RELATING
TO MANUFACTURE
OF CONTROLLED
SUBSTANCES.—
‘‘(1) CONTROLLED
SUBSTANCE
DEFINED.—In
this subsection, the term ‘controlled substance’ has
the meaning given that term in section 102(6) of the
Controlled Substances Act (21 U.S.C. 802(6)).
‘‘(2) PROHIBITION.—It shall be unlawful for
any person—
‘‘(A) to teach or demonstrate the manufac-
ture of a controlled substance, or to distribute
by any means information pertaining to, in
whole or in part, the manufacture or use of a
controlled substance, with the intent that the
teaching, demonstration, or information be used
for, or in furtherance of, an activity that con-
stitutes a Federal crime; or
‘‘(B) to teach or demonstrate to any per-
son the manufacture of a controlled substance,
or to distribute to any person, by any means,
information pertaining to, in whole or in part,
the manufacture or use of a controlled sub-
stance, knowing that such person intends to use
the teaching, demonstration, or information for,
or in furtherance of, an activity that constitutes
a Federal crime.
‘‘(b) PENALTY.—Any person who violates subsection
(a) shall be fined under this title, imprisoned not more
than 10 years, or both.’’.
(b) CLERICAL AMENDMENT.—The table of chapters
at the beginning of part I of title 18, United States Code,
is amended by inserting after the item relating to chapter
21 the following new item:
‘‘22. Controlled Substances ............................................................
421’’.
SEC. 6. NOTICE; CLARIFICATION.
(a) NOTICE OF ISSUANCE.—Section 3103a of title
18, United States Code, is amended by adding at the end
the following new sentence: ‘‘With respect to any issuance
under this section or any other provision of law (including
section 3117 and any rule), any notice required, or that
may be required, to be given may be delayed pursuant to
the standards, terms, and conditions set forth in section
2705, unless otherwise expressly provided by statute.’’.
(b) CLARIFICATION.—(1) Section 2(e) of Public Law
95–78 (91 Stat. 320) is amended by adding at the end
the following:
‘‘Subdivision (d) of such rule, as in effect on this date,
is amended by inserting ‘tangible’ before ‘property’ each
place it occurs.’’.
(2) The amendment made by paragraph (1) shall
take effect on the date of the enactment of this Act.
SEC. 7. TRAINING FOR DRUG ENFORCEMENT ADMINISTRA-
TION AND STATE AND LOCAL LAW ENFORCE-
MENT PERSONNEL RELATING TO CLANDES-
TINE LABORATORIES.
(a) IN GENERAL.—
(1) REQUIREMENT.—The Administrator of the
Drug Enforcement Administration shall carry out
the programs described in subsection (b) with re-
spect to the law enforcement personnel of States and
localities determined by the Administrator to have
significant levels of methamphetamine-related or am-
phetamine-related crime or projected by the Admin-
istrator to have the potential for such levels of crime
in the future.
(2) DURATION.—The duration of any program
under that subsection may not exceed 3 years.
(b) COVERED PROGRAMS.—The programs described
in this subsection are as follows:
(1) ADVANCED MOBILE CLANDESTINE LABORA-
TORY
TRAINING
TEAMS.—A program of advanced
mobile clandestine laboratory training teams, which
shall provide information and training to State and
local law enforcement personnel in techniques uti-
lized in conducting undercover investigations and
conspiracy cases, and other information designed to
assist in the investigation of the illegal manufac-
turing and trafficking of amphetamine and meth-
amphetamine.
(2) BASIC CLANDESTINE LABORATORY CERTIFI-
CATION TRAINING.—A program of basic clandestine
laboratory certification training, which shall provide
information and training—
(A) to Drug Enforcement Administration
personnel and State and local law enforcement
personnel for purposes of enabling such per-
sonnel to meet any certification requirements
under law with respect to the handling of
wastes created by illegal amphetamine and
methamphetamine laboratories; and
(B) to State and local law enforcement
personnel for purposes of enabling such per-
sonnel to provide the information and training
covered by subparagraph (A) to other State and
local law enforcement personnel.
(3) CLANDESTINE
LABORATORY
RECERTIFI-
CATION AND AWARENESS TRAINING.—A program of
clandestine laboratory recertification and awareness
training, which shall provide information and train-
ing to State and local law enforcement personnel for
purposes of enabling such personnel to provide recer-
tification and awareness training relating to clandes-
tine laboratories to additional State and local law
enforcement personnel.
(c) AUTHORIZATION
OF APPROPRIATIONS.—There
are authorized to be appropriated for each of fiscal years
2000, 2001, and 2002 amounts as follows:
(1) $1,500,000 to carry out the program de-
scribed in subsection (b)(1).
(2) $3,000,000 to carry out the program de-
scribed in subsection (b)(2).
(3) $1,000,000 to carry out the program de-
scribed in subsection (b)(3).
SEC. 8. COMBATTING METHAMPHETAMINE AND AMPHET-
AMINE IN HIGH INTENSITY DRUG TRAF-
FICKING AREAS.
(a) IN GENERAL.—
(1) IN
GENERAL.—The Director of National
Drug Control Policy shall use amounts available
under this section to combat the trafficking of meth-
amphetamine and amphetamine in areas designated
by the Director as high intensity drug trafficking
areas.
(2) ACTIVITIES.—In meeting the requirement
in paragraph (1), the Director shall provide funds
for—
(A) employing additional Federal law en-
forcement personnel, or facilitating the employ-
ment of additional State and local law enforce-
ment personnel, including agents, investigators,
prosecutors, laboratory technicians, chemists,
investigative assistants, and drug-prevention
specialists; and
(B) such other activities as the Director
considers appropriate.
(b) AUTHORIZATION OF APPROPRIATIONS.—There is
authorized to be appropriated to carry out this section—
(1) $15,000,000 for fiscal year 2000; and
(2) such sums as may be necessary for each of
fiscal years 2001 through 2004.
(c) APPORTIONMENT OF FUNDS.—
(1) FACTORS IN APPORTIONMENT.—The Direc-
tor shall apportion amounts appropriated for a fiscal
year pursuant to the authorization of appropriations
in subsection (b) for activities under subsection (a)
among and within areas designated by the Director
as high intensity drug trafficking areas based on the
following factors:
(A) The number of methamphetamine
manufacturing facilities and amphetamine man-
ufacturing facilities discovered by Federal,
State, or local law enforcement officials in the
previous fiscal year.
(B) The number of methamphetamine
prosecutions and amphetamine prosecutions in
Federal, State, or local courts in the previous
fiscal year.
(C) The number of methamphetamine ar-
rests and amphetamine arrests by Federal,
State, or local law enforcement officials in the
previous fiscal year.
(D) The amounts of methamphetamine,
amphetamine, or listed chemicals (as that term
is defined in section 102(33) of the Controlled
Substances Act (21 U.S.C. 802(33)) seized by
Federal, State, or local law enforcement offi-
cials in the previous fiscal year.
(E) Intelligence and predictive data from
the Drug Enforcement Administration and the
Department of Health and Human Services
showing patterns and trends in abuse, traf-
ficking, and transportation in methamphet-
amine, amphetamine, and listed chemicals (as
that term is so defined).
(2) CERTIFICATION.—Before the Director ap-
portions any funds under this subsection to a high
intensity drug trafficking area, the Director shall
certify that the law enforcement entities responsible
for clandestine methamphetamine and amphetamine
laboratory seizures in that area are providing labora-
tory seizure data to the national clandestine labora-
tory database at the El Paso Intelligence Center.
(d) LIMITATION ON ADMINISTRATIVE COSTS.—Not
more than 5 percent of the amount appropriated in a fiscal
year pursuant to the authorization of appropriations for
that fiscal year in subsection (b) may be available in that
fiscal year for administrative costs associated with activi-
ties under subsection (a).
SEC. 9. COMBATING AMPHETAMINE AND METHAMPHET-
AMINE MANUFACTURING AND TRAFFICKING.
(a) ACTIVITIES.—In order to combat the illegal man-
ufacturing and trafficking in amphetamine and meth-
amphetamine, the Administrator of the Drug Enforcement
Administration may—
(1) assist State and local law enforcement in
small and mid-sized communities in all phases of in-
vestigations related to such manufacturing and traf-
ficking, including assistance with foreign-language
interpretation;
(2) staff additional regional enforcement and
mobile enforcement teams related to such manufac-
turing and trafficking;
(3) establish additional resident offices and
posts of duty to assist State and local law enforce-
ment in rural areas in combating such manufac-
turing and trafficking;
(4) provide the Special Operations Division of
the Administration with additional agents and staff
to collect, evaluate, interpret, and disseminate crit-
ical intelligence targeting the command and control
operations of major amphetamine and methamphet-
amine manufacturing and trafficking organizations;
and
(5) carry out such other activities as the Ad-
ministrator considers appropriate.
(b) ADDITIONAL POSITIONS AND PERSONNEL.—In
carrying out activities under subsection (a), the Adminis-
trator may establish in the Administration not more than
50 full-time positions, including not more than 31 special-
agent positions, and may appoint personnel to such posi-
tions.
(c) AUTHORIZATION
OF APPROPRIATIONS.—There
are authorized to be appropriated for the Drug Enforce-
ment Administration for each fiscal year after fiscal year
1999, $6,500,000 for purposes of carrying out the activi-
ties authorized by subsection (a) and employing personnel
in positions established under subsection (b).
SEC. 10. ENVIRONMENTAL HAZARDS ASSOCIATED WITH IL-
LEGAL MANUFACTURE OF AMPHETAMINE
AND METHAMPHETAMINE.
(a) USE OF AMOUNTS OR DEPARTMENT OF JUSTICE
ASSETS FORFEITURE FUND.—Section 524(c)(1)(E) of
title 28, United States Code, is amended—
(1) by inserting ‘‘(i) for’’ before ‘‘disburse-
ments’’;
(2) by inserting ‘‘and’’ after the semicolon; and
(3) by adding at the end the following:
‘‘(ii) for payment for—
‘‘(I) costs incurred by or on behalf of the
Department of Justice in connection with the
removal, for purposes of Federal forfeiture and
disposition, of any hazardous substance or pol-
lutant or contaminant associated with the ille-
gal manufacture of amphetamine or meth-
amphetamine; and
‘‘(II) costs incurred by or on behalf of a
State or local government in connection with
such removal in any case in which such State
or local government has assisted in a Federal
prosecution relating to amphetamine or meth-
amphetamine, to the extent such costs exceed
equitable sharing payments made to such State
or local government in such case;’’.
(b) GRANTS UNDER DRUG CONTROL AND SYSTEM
IMPROVEMENT GRANT PROGRAM.—Section 501(b)(3) of
the Omnibus Crime Control and Safe Streets Act of 1968
is amended by inserting before the semicolon the following:
‘‘and to remove any hazardous substance or pollutant or
contaminant associated with the illegal manufacture of
amphetamine or methamphetamine’’.
(c) AMOUNTS SUPPLEMENT AND NOT SUPPLANT.—
(1) ASSETS FORFEITURE FUND.—Any amounts
made available from the Department of Justice As-
sets Forfeiture Fund in a fiscal year by reason of
the amendment made by subsection (a) shall supple-
ment, and not supplant, any other amounts made
available to the Department of Justice in such fiscal
year from other sources for payment of costs de-
scribed in section 524(c)(1)(E)(ii) of title 28, United
States Code, as so amended.
(2) GRANT
PROGRAM.—Any amounts made
available in a fiscal year under the grant program
under section 501(b)(3) of the Omnibus Crime Con-
trol and Safe Streets Act of 1968 for the removal
of hazardous substances or pollutants or contami-
nants associated with the illegal manufacture of am-
phetamine or methamphetamine by reason of the
amendment made by subsection (b) shall supple-
ment, and not supplant, any other amounts made
available in such fiscal year from other sources for
such removal.
SEC. 11. ANTIDRUG MESSAGES ON FEDERAL GOVERNMENT
INTERNET WEBSITES.
Not later than 90 days after the date of the enact-
ment of this Act, the head of each department, agency,
and establishment of the Federal Government shall, in
consultation with the Director of the Office of National
Drug Control Policy, place antidrug messages on appro-
priate Internet websites controlled by such department,
agency, or establishment which messages shall, where ap-
propriate, contain an electronic hyperlink to the Internet
website, if any, of the Office.
SEC. 12. MAIL ORDER REQUIREMENTS.
Section 310(b)(3) of the Controlled Substances Act
(21 U.S.C. 830(b)(3)) is amended—
(1) by redesignating subparagraphs (A) and
(B) as subparagraphs (B) and (C), respectively;
(2) by inserting before subparagraph (B), as so
redesignated, the following new subparagraph (A):
‘‘(A) As used in this paragraph:
‘‘(i) The term ‘drug product’ means
an active ingredient in dosage form that
has been approved or otherwise may be
lawfully marketed under the Food, Drug,
and Cosmetic Act for distribution in the
United States.
‘‘(ii) The term ‘valid prescription’
means a prescription which is issued for a
legitimate medical purpose by an individual
practitioner licensed by law to administer
and prescribe the drugs concerned and act-
ing in the usual course of the practitioner’s
professional practice.’’;
(3) in subparagraph (B), as so redesignated, by
inserting ‘‘or who engages in an export transaction’’
after ‘‘nonregulated person’’; and
(4) adding at the end the following:
‘‘(D) Except as provided in subparagraph
(E), the following distributions to a nonregu-
lated person, and the following export trans-
actions, shall not be subject to the reporting re-
quirement in subparagraph (B):
‘‘(i) Distributions of sample packages
of drug products when such packages con-
tain not more than 2 solid dosage units or
the equivalent of 2 dosage units in liquid
form, not to exceed 10 milliliters of liquid
per package, and not more than one pack-
age is distributed to an individual or resi-
dential address in any 30-day period.
‘‘(ii) Distributions of drug products by
retail distributors that may not include
face-to-face transactions to the extent that
such distributions are consistent with the
activities authorized for a retail distributor
as specified in section 102(46).
‘‘(iii) Distributions of drug products
to a resident of a long term care facility
(as that term is defined in regulations pre-
scribed by the Attorney General) or dis-
tributions of drug products to a long term
care facility for dispensing to or for use by
a resident of that facility.
‘‘(iv) Distributions of drug products
pursuant to a valid prescription.
‘‘(v) Exports which have been re-
ported to the Attorney General pursuant to
section 1004 or 1018 or which are subject
to 
a 
waiver 
granted 
under 
section
1018(e)(2).
‘‘(vi) Any quantity, method, or type of
distribution or any quantity, method, or
type of distribution of a specific listed
chemical (including specific formulations or
drug products) or of a group of listed
chemicals (including specific formulations
or drug products) which the Attorney Gen-
eral has excluded by regulation from such
reporting requirement on the basis that
such reporting is not necessary for the en-
forcement of this title or title III.
‘‘(E) The Attorney General may revoke
any or all of the exemptions listed in subpara-
graph (D) for an individual regulated person if
he finds that drug products distributed by the
regulated person are being used in violation of
this title or title III. The regulated person shall
be notified of the revocation, which will be ef-
fective upon receipt by the person of such no-
tice, as provided in section 1018(c)(1), and
shall have the right to an expedited hearing as
provided in section 1018(c)(2).’’.
SEC. 13. THEFT AND TRANSPORTATION OF ANHYDROUS
AMMONIA FOR PURPOSES OF ILLICIT PRO-
DUCTION OF CONTROLLED SUBSTANCES.
(a) IN GENERAL.—Part D of the Controlled Sub-
stances Act (21 U.S.C. 841 et seq.) is amended by adding
at the end the following:
‘‘ANHYDROUS AMMONIA
‘‘SEC. 423 (a) It is unlawful for any person—
‘‘(1) to steal anhydrous ammonia, or
‘‘(2) to transport stolen anhydrous ammonia
across State lines,
knowing, intending, or having reasonable cause to believe
that such anhydrous ammonia will be used to manufacture
a controlled substance in violation of this part.
‘‘(b) Any person who violates subsection (a) shall be
imprisoned or fined, or both, in accordance with section
403(d) as if such violation were a violation of a provision
of section 403.’’.
(b) CLERICAL AMENDMENT.—The table of contents
for that Act is amended by inserting after the item relat-
ing to section 421 the following new items:
‘‘Sec. 422. Drug paraphernalia.
‘‘Sec. 423. Anhydrous ammonia.’’.
(c) ASSISTANCE FOR CERTAIN RESEARCH.—
(1) AGREEMENT.—The Administrator of the
Drug Enforcement Administration shall seek to
enter into an agreement with Iowa State University
in order to permit the University to continue and ex-
pand its current research into the development of
inert agents that, when added to anhydrous ammo-
nia, eliminate the usefulness of anhydrous ammonia
as an ingredient in the production of methamphet-
amine.
(2) REIMBURSABLE
PROVISION
OF
FUNDS.—
The agreement under paragraph (1) may provide for
the provision to Iowa State University, on a reim-
bursable basis, of $500,000 for purposes the activi-
ties specified in that paragraph.
(3) AUTHORIZATION
OF
APPROPRIATIONS.—
There is hereby authorized to be appropriated for
the Drug Enforcement Administration for fiscal year
2000, $500,000 for purposes of carrying out the
agreement under this subsection.
SEC. 14. REPORT ON METHAMPHETAMINE CONSUMPTION
IN RURAL AREAS, SUBURBAN AREAS, SMALL
CITIES, MIDSIZE CITIES, AND LARGE CITIES.
(a) IN GENERAL.—The Secretary of Health and
Human Services shall submit to the designated commit-
tees of Congress on an annual basis a report on the prob-
lems caused by methamphetamine consumption in rural
areas, suburban areas, small cities, midsize cities, and
large cities.
(b) CONCERNS ADDRESSED.—Each report submitted
under this section shall include an analysis of—
(1) the manner in which methamphetamine con-
sumption in rural areas differs from methamphet-
amine consumption in areas with larger populations,
and the means by which to accurately measure those
differences;
(2) the incidence of methamphetamine abuse in
rural areas and the treatment resources available to
deal with methamphetamine addiction in those
areas;
(3) any relationship between methamphetamine
consumption in rural areas and a lack of substance
abuse treatment in those areas; and
(4) any relationship between geographic dif-
ferences in the availability of substance abuse treat-
ment and the geographic distribution of the meth-
amphetamine abuse problem in the United States.
(c) DEFINITIONS.—In this section:
(1) The term ‘‘designated committees of Con-
gress’’ means the following:
(A) The Committees on the Judiciary and
Appropriations of the Senate.
(B) The Committees on the Judiciary and
Appropriations of the House of Representatives.
(2) The term ‘‘large city’’ means any city that
is not a small city or a midsize city.
(3) The term ‘‘midsize city’’ means a city with
a population under 250,000 and over 20,000.
(4) The term ‘‘rural area’’ means a county or
parish with a population under 50,000.
(5) The term ‘‘small city’’ means a city with a
population under 20,000.
SEC. 15. EXPANSION OF METHAMPHETAMINE ABUSE PRE-
VENTION EFFORTS.
(a) EXPANSION OF EFFORTS.—Section 515 of the
Public Health Service Act (42 U.S.C. 290bb–21) is
amended by adding at the end the following:
‘‘(e)(1) The Administrator may make grants to and
enter into contracts and cooperative agreements with pub-
lic and nonprofit private entities to enable such entities—
‘‘(A) to carry out school-based programs con-
cerning the dangers of abuse of and addiction to
methamphetamine and other illicit drugs, using
methods that are effective and science-based, includ-
ing initiatives that give students the responsibility to
create their own anti-drug abuse education programs
for their schools; and
‘‘(B) to carry out community-based abuse and
addiction prevention programs relating to meth-
amphetamine and other illicit drugs that are effec-
tive and science-based.
‘‘(2) Amounts made available under a grant, contract
or cooperative agreement under paragraph (1) shall be
used for planning, establishing, or administering preven-
tion programs relating to methamphetamine and other il-
licit drugs in accordance with paragraph (3).
‘‘(3)(A) Amounts provided under this subsection may
be used—
‘‘(i) to carry out school-based programs that
are focused on those districts with high or increasing
rates of methamphetamine abuse and addiction and
targeted at populations which are most at risk to
start abuse of methamphetamine and other illicit
drugs;
‘‘(ii) to carry out community-based prevention
programs that are focused on those populations
within the community that are most at-risk for
abuse of and addiction to methamphetamine and
other illicit drugs;
‘‘(iii) to assist local government entities to con-
duct appropriate prevention activities relating to
methamphetamine and other illicit drugs;
‘‘(iv) to train and educate State and local law
enforcement officials, prevention and education offi-
cials, members of community anti-drug coalitions
and parents on the signs of abuse of and addiction
to methamphetamine and other illicit drugs, and the
options for treatment and prevention;
‘‘(v) for planning, administration, and edu-
cational activities related to the prevention of abuse
of and addiction to methamphetamine and other il-
licit drugs;
‘‘(vi) for the monitoring and evaluation of pre-
vention activities relating to methamphetamine and
other illicit drugs, and reporting and disseminating
resulting information to the public; and
‘‘(vii) for targeted pilot programs with evalua-
tion components to encourage innovation and experi-
mentation with new methodologies.
‘‘(B) The Administrator shall give priority in making
grants under this subsection to rural and urban areas that
are experiencing a high rate or rapid increases in meth-
amphetamine abuse and addiction.
‘‘(4)(A) Not less than $500,000 of the amount avail-
able in each fiscal year to carry out this subsection shall
be made available to the Administrator, acting in consulta-
tion with other Federal agencies, to support and conduct
periodic analyses and evaluations of effective prevention
programs for abuse of and addiction to methamphetamine
and other illicit drugs and the development of appropriate
strategies for disseminating information about and imple-
menting these programs.
‘‘(B) The Administrator shall submit to the commit-
tees of Congress referred to in subparagraph (C) an an-
nual report with the results of the analyses and evaluation
under subparagraph (A).
‘‘(C) The committees of Congress referred to in this
subparagraph are the following:
‘‘(i) The Committees on Health, Education,
Labor, and Pensions, the Judiciary, and Appropria-
tions of the Senate.
‘‘(ii) The Committees on Commerce, the Judici-
ary, and Appropriations of the House of Representa-
tives.’’.
(b) AUTHORIZATION OF APPROPRIATIONS FOR EX-
PANSION OF ABUSE PREVENTION EFFORTS AND PRACTI-
TIONER REGISTRATION REQUIREMENTS.—There is au-
thorized to be appropriated to carry out section 515(e) of
the Public Health Service Act (as added by subsection (a))
and section 303(g)(2) of the Controlled Substances Act
(as added by section 18(a) of this Act), $15,000,000 for
fiscal year 2000, and such sums as may be necessary for
each succeeding fiscal year.
SEC. 16. EXPANSION OF METHAMPHETAMINE RESEARCH.
Section 464N of the Public Health Service Act (42
U.S.C. 285o–2) is amended by adding at the end the fol-
lowing:
‘‘(c) METHAMPHETAMINE RESEARCH.—
‘‘(1) 
GRANTS
OR
COOPERATIVE
AGREE-
MENTS.—The Director of the Institute may make
grants or enter into cooperative agreements to ex-
pand the current and on-going interdisciplinary re-
search and clinical trials with treatment centers of
the National Drug Abuse Treatment Clinical Trials
Network relating to methamphetamine abuse and
addiction and other biomedical, behavioral, and so-
cial issues related to methamphetamine abuse and
addiction.
‘‘(2) USE OF FUNDS.—Amounts made available
under a grant or cooperative agreement under para-
graph (1) for methamphetamine abuse and addiction
may be used for research and clinical trials relating
to—
‘‘(A) the effects of methamphetamine
abuse on the human body, including the brain;
‘‘(B) the addictive nature of methamphet-
amine and how such effects differ with respect
to different individuals;
‘‘(C) the connection between methamphet-
amine abuse and mental health;
‘‘(D) the identification and evaluation of
the most effective methods of prevention of
methamphetamine abuse and addiction;
‘‘(E) the identification and development of
the most effective methods of treatment of
methamphetamine addiction, including pharma-
cological treatments;
‘‘(F) risk factors for methamphetamine
abuse;
‘‘(G) effects of methamphetamine abuse
and addiction on pregnant women and their
fetuses;
‘‘(H) cultural, social, behavioral, neuro-
logical and psychological reasons that individ-
uals abuse methamphetamine, or refrain from
abusing methamphetamine.
‘‘(3) RESEARCH RESULTS.—The Director shall
promptly disseminate research results under this
subsection to Federal, State and local entities in-
volved in combating methamphetamine abuse and
addiction.
‘‘(4) AUTHORIZATION OF APPROPRIATIONS.—
‘‘(A) 
AUTHORIZATION
OF
APPROPRIA-
TIONS.—There is authorized to be appropriated
to carry out paragraph (1), such sums as may
be necessary for each fiscal year.
‘‘(B) 
SUPPLEMENT
NOT
SUPPLANT.—
Amounts appropriated pursuant to the author-
ization of appropriations in subparagraph (A)
for a fiscal year shall supplement and not sup-
plant any other amounts appropriated in such
fiscal year for research on methamphetamine
abuse and addiction.’’.
SEC. 17. STUDY OF METHAMPHETAMINE TREATMENT.
(a) STUDY.—
(1) REQUIREMENT.—The Secretary of Health
and Human Services shall, in consultation with the
Institute of Medicine of the National Academy of
Sciences, conduct a study on the development of
medications for the treatment of addiction to am-
phetamine and methamphetamine.
(2) REPORT.—Not later than nine months after
the date of the enactment of this Act, the Secretary
shall submit to the Committees on the Judiciary of
the Senate and House of Representatives a report on
the results of the study conducted under paragraph
(1).
(b) AUTHORIZATION
OF APPROPRIATIONS.—There
are hereby authorized to be appropriated for the Depart-
ment of Health and Human Services for fiscal year 2000
such sums as may be necessary to meet the requirements
of subsection (a).
SEC. 18. REGISTRATION REQUIREMENTS FOR PRACTI-
TIONERS WHO DISPENSE CERTAIN NARCOTIC
DRUGS FOR MAINTENANCE TREATMENT OR
DETOXIFICATION TREATMENT.
(a) IN GENERAL.—Section 303(g) of the Controlled
Substances Act (21 U.S.C. 823(g)) is amended—
(1) in paragraph (2), by striking ‘‘(A) security’’
and inserting ‘‘(i) security’’, and by striking ‘‘(B)
the maintenance’’ and inserting ‘‘(ii) the mainte-
nance’’;
(2) by redesignating paragraphs (1) through
(3) as subparagraphs (A) through (C), respectively;
(3) by inserting ‘‘(1)’’ after ‘‘(g)’’;
(4) by striking ‘‘Practitioners who dispense’’
and inserting ‘‘Except as provided in paragraph (2),
practitioners who dispense’’; and
(5) by adding at the end the following:
‘‘(2)(A) Subject to subparagraphs (D) and (G),
the requirements of paragraph (1) are waived in the
case of the prescribing or dispensing, by a practi-
tioner, of narcotic drugs in schedule IV or V or com-
binations of such drugs if the practitioner meets the
conditions specified in subparagraph (B) and the
narcotic drugs or combinations of such drugs meet
the conditions specified in subparagraph (C).
‘‘(B) For purposes of subparagraph (A), the
conditions specified in this subparagraph with re-
spect to a practitioner are that, before prescribing of
dispensing narcotic drugs in schedule IV or V, or
combinations of such drugs, to patients for mainte-
nance or detoxification treatment, the practitioner
submit to the Secretary a notification of the intent
of the practitioner to begin dispensing the drugs or
combinations for such purpose, and that the notifi-
cation contain the following certifications by the
practitioner:
‘‘(i) The practitioner is a physician li-
censed under State law, and the practitioner
has demonstrable training or experience and the
ability to treat and manage opiate-dependent
patients.
‘‘(ii) With respect to patients to whom the
practitioner will provide such drugs or combina-
tions of drugs, the practitioner has the dem-
onstrated capacity to refer the patients for ap-
propriate counseling and other appropriate an-
cillary services.
‘‘(iii) In any case in which the practitioner
is not in a group practice, the total number of
such patients of the practitioner at any one
time will not exceed the applicable number. For
purposes of this clause, the applicable number
is 20, except that the Secretary may by regula-
tion change such total number.
‘‘(iv) In any case in which the practitioner
is in a group practice, the total number of such
patients of the group practice at any one time
will not exceed the applicable number. For pur-
poses of this clause, the applicable number is
20, except that the Secretary may by regulation
change such total number, and the Secretary
for such purposes may by regulation establish
different categories on the basis of the number
of practitioners in a group practice and estab-
lish for the various categories different numer-
ical limitations on the number of such patients
that the group practice may have.
‘‘(C) For purposes of subparagraph (A), the
conditions specified in this subparagraph with re-
spect to narcotic drugs in schedule IV or V or com-
binations of such drugs are as follows:
‘‘(i) The drugs or combinations of drugs
have, under the Federal Food, Drug and Cos-
metic Act or section 351 of the Public Health
Service Act, been approved for use in mainte-
nance or detoxification treatment.
‘‘(ii) The drugs or combinations of drugs
have not been the subject of an adverse deter-
mination. For purposes of this clause, an ad-
verse determination is a determination pub-
lished in the Federal Register and made by the
Secretary, after consultation with the Attorney
General, that the use of the drugs or combina-
tions of drugs for maintenance or detoxification
treatment requires additional standards respect-
ing the qualifications of practitioners to provide
such treatment, or requires standards respect-
ing the quantities of the drugs that may be pro-
vided for unsupervised use.
‘‘(D)(i) A waiver under subparagraph (A) with
respect to a practitioner is not in effect unless (in
addition to conditions under subparagraphs (B) and
(C)) the following conditions are met:
‘‘(I) The notification under subparagraph
(B) is in writing and states the name of the
practitioner.
‘‘(II) The notification identifies the reg-
istration issued for the practitioner pursuant to
subsection (f).
‘‘(III) If the practitioner is a member of a
group practice, the notification states the
names of the other practitioners in the practice
and identifies the registrations issued for the
other practitioners pursuant to subsection (f).
‘‘(IV) A period of 45 days has elapsed
after the date on which the notification was
submitted, and during such period the practi-
tioner does not receive from the Secretary a
written notice that one or more of the condi-
tions specified in subparagraph (B), subpara-
graph (C), or this subparagraph, have not been
met.
‘‘(ii) The Secretary shall provide to the Attor-
ney General such information contained in notifica-
tions under subparagraph (B) as the Attorney Gen-
eral may request.
‘‘(E) If in violation of subparagraph (A) a prac-
titioner dispenses narcotic drugs in schedule IV or V
or combinations of such drugs for maintenance
treatment or detoxification treatment, the Attorney
General may, for purposes of section 304(a)(4), con-
sider the practitioner to have committed an act that
renders the registration of the practitioner pursuant
to subsection (f) to be inconsistent with the public
interest.
‘‘(F) In this paragraph, the term ‘group prac-
tice’ has the meaning given such term in section
1877(h)(4) of the Social Security Act.
‘‘(G)(i) This paragraph takes effect on the date
of enactment of the Methamphetamine Anti-Pro-
liferation Act of 1999, and remains in effect there-
after except as provided in clause (iii) (relating to a
decision by the Secretary or the Attorney General
that this paragraph should not remain in effect).
‘‘(ii) For the purposes relating to clause (iii),
the Secretary and the Attorney General shall, during
the 3-year period beginning on the date of enact-
ment of the Methamphetamine Anti-Proliferation
Act of 1999, make determinations in accordance
with the following:
‘‘(I)(aa) The Secretary shall—
‘‘(aaa) make a determination of
whether treatments provided under waivers
under subparagraph (A) have been effec-
tive forms of maintenance treatment and
detoxification treatment in clinical settings;
‘‘(bbb) make a determination regard-
ing whether such waivers have significantly
increased (relative to the beginning of such
period) the availability of maintenance
treatment and detoxification treatment;
and
‘‘(ccc) make a determination regard-
ing whether such waivers have adverse con-
sequences for the public health.
‘‘(bb) In making determinations under this
subclause, the Secretary—
‘‘(aa) may collect data from the prac-
titioners for whom waivers under subpara-
graph (A) are in effect;
‘‘(bb) shall issue appropriate guide-
lines or regulations (in accordance with
procedures for substantive rules under sec-
tion 553 of title 5, United States Code)
specifying the scope of the data that will
be required to be provided under this sub-
clause and the means through which the
data will be collected;
‘‘(cc) shall, with respect to collecting
such data, comply with applicable provi-
sions of chapter 6 of title 5, United States
Code (relating to a regulatory flexibility
analysis), and of chapter 8 of such title
(relating to congressional review of agency
rulemaking); and
‘‘(dd) shall make a determination re-
garding whether such waivers have adverse
consequences for the public health.
‘‘(II) The Attorney General shall—
‘‘(aa) make a determination of the ex-
tent to which there have been violations of
the numerical limitations established under
subparagraph (B) for the number of indi-
viduals to whom a practitioner may provide
treatment; and
‘‘(bb) make a determination regarding
whether waivers under subparagraph (A)
have increased (relative to the beginning of
such period) the extent to which narcotic
drugs in schedule IV or V or combinations
of such drugs are being dispensed or pos-
sessed in violation of this Act.
‘‘(iii) If, before the expiration of the period
specified in clause (ii), the Secretary or the Attorney
General publishes in the Federal Register a decision,
made on the basis of determinations under such
clause, that this paragraph should not remain in ef-
fect, this paragraph ceases to be in effect 60 days
after the date on which the decision is so published.
The Secretary shall, in making any such decision,
consult with the Attorney General, and shall, in pub-
lishing the decision in the Federal Register, include
any comments received from the Attorney General
for inclusion in the publication. The Attorney Gen-
eral shall, in making any such decision, consult with
the Secretary, and shall, in publishing the decision
in the Federal Register, include any comments re-
ceived from the Secretary for inclusion in the publi-
cation.
‘‘(H) During the 3-year period beginning on the
date of enactment of the Methamphetamine Anti-
Proliferation Act 1999, a State may not preclude a
practitioner from dispensing narcotic drugs in sched-
ule IV or V, or combinations of such drugs, to pa-
tients for maintenance or detoxification treatment in
accordance with this paragraph, or the other amend-
ments made by section 22 of that Act, unless, before
the expiration of that 3-year period, the State enacts
a law prohibiting a practitioner from dispensing
such drugs or combination of drugs.’’.
(b) CONFORMING AMENDMENTS.—Section 304 of the
Controlled Substances Act (21 U.S.C. 824) is amended—
(1) in subsection (a), in the matter following
paragraph (5), by striking ‘‘section 303(g)’’ each
place the term appears and inserting ‘‘section
303(g)(1)’’; and
(2) in subsection (d), by striking ‘‘section
303(g)’’ and inserting ‘‘section 303(g)(1)’’.
SEC. 19. ENHANCED PUNISHMENT OF METHAMPHETAMINE
LABORATORY OPERATORS.
(a) FEDERAL SENTENCING GUIDELINES.—
(1) IN
GENERAL.—Pursuant to its authority
under section 994(p) of title 28, United States Code,
the United States Sentencing Commission shall
amend the Federal sentencing guidelines in accord-
ance with paragraph (2) with respect to any offense
relating to the manufacture, attempt to manufac-
ture, or conspiracy to manufacture amphetamine or
methamphetamine in violation of—
(A) the Controlled Substances Act (21
U.S.C. 801 et seq.);
(B) the Controlled Substances Import and
Export Act (21 U.S.C. 951 et seq.); or
(C) the Maritime Drug Law Enforcement
Act (46 U.S.C. App. 1901 et seq.).
(2) REQUIREMENTS.—In carrying out this
paragraph, the United States Sentencing Commis-
sion shall—
(A) if the offense created a substantial risk
of harm to human life (other than a life de-
scribed in subparagraph (B)) or the environ-
ment, increase the base offense level for the
offense—
(i) by not less than 3 offense levels
above the applicable level in effect on the
date of enactment of this Act; or